Group A and group B streptococcal vaccine development - A round table presentation

J. B. Dale; P. P. Cleary; V. A. Fischetti; D. L. Kasper; J. M. Musser; J. B. Zabriskie

doi:10.1007/978-1-4899-1825-3_205

Group A and group B streptococcal vaccine development - A round table presentation

J. B. Dale, P. P. Cleary, V. A. Fischetti, D. L. Kasper, J. M. Musser, J. B. Zabriskie

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

The data presented above provide a broad overview of ongoing work to develop vaccines against group A and group B streptococcal infections. The encouraging results of human trials with conjugate group B polysaccharide vaccines suggest that this approach will lead to a safe and effective method for preventing these devastating infections in new-born infants. The results of preclinical studies of the various strategies to develop group A streptococcal vaccines are also encouraging. Whether one approach will be more advantageous or efficacious than another will need to await clinical trials. Nevertheless, we predict that in the next decade we will make significant strides in preventing streptococcal infections and their complications.

Original language	English (US)
Pages (from-to)	863-868
Number of pages	6
Journal	Advances in experimental medicine and biology
Volume	418
DOIs	https://doi.org/10.1007/978-1-4899-1825-3_205
State	Published - 1997

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1007/978-1-4899-1825-3_205

Cite this

@article{d1d8411d78d446eb97973d95948760d1,

title = "Group A and group B streptococcal vaccine development - A round table presentation",

abstract = "The data presented above provide a broad overview of ongoing work to develop vaccines against group A and group B streptococcal infections. The encouraging results of human trials with conjugate group B polysaccharide vaccines suggest that this approach will lead to a safe and effective method for preventing these devastating infections in new-born infants. The results of preclinical studies of the various strategies to develop group A streptococcal vaccines are also encouraging. Whether one approach will be more advantageous or efficacious than another will need to await clinical trials. Nevertheless, we predict that in the next decade we will make significant strides in preventing streptococcal infections and their complications.",

author = "Dale, {J. B.} and Cleary, {P. P.} and Fischetti, {V. A.} and Kasper, {D. L.} and Musser, {J. M.} and Zabriskie, {J. B.}",

year = "1997",

doi = "10.1007/978-1-4899-1825-3_205",

language = "English (US)",

volume = "418",

pages = "863--868",

journal = "Advances in experimental medicine and biology",

issn = "0065-2598",

publisher = "Springer New York",

}

TY - JOUR

T1 - Group A and group B streptococcal vaccine development - A round table presentation

AU - Dale, J. B.

AU - Cleary, P. P.

AU - Fischetti, V. A.

AU - Kasper, D. L.

AU - Musser, J. M.

AU - Zabriskie, J. B.

PY - 1997

Y1 - 1997

N2 - The data presented above provide a broad overview of ongoing work to develop vaccines against group A and group B streptococcal infections. The encouraging results of human trials with conjugate group B polysaccharide vaccines suggest that this approach will lead to a safe and effective method for preventing these devastating infections in new-born infants. The results of preclinical studies of the various strategies to develop group A streptococcal vaccines are also encouraging. Whether one approach will be more advantageous or efficacious than another will need to await clinical trials. Nevertheless, we predict that in the next decade we will make significant strides in preventing streptococcal infections and their complications.

AB - The data presented above provide a broad overview of ongoing work to develop vaccines against group A and group B streptococcal infections. The encouraging results of human trials with conjugate group B polysaccharide vaccines suggest that this approach will lead to a safe and effective method for preventing these devastating infections in new-born infants. The results of preclinical studies of the various strategies to develop group A streptococcal vaccines are also encouraging. Whether one approach will be more advantageous or efficacious than another will need to await clinical trials. Nevertheless, we predict that in the next decade we will make significant strides in preventing streptococcal infections and their complications.

UR - http://www.scopus.com/inward/record.url?scp=0030771818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030771818&partnerID=8YFLogxK

U2 - 10.1007/978-1-4899-1825-3_205

DO - 10.1007/978-1-4899-1825-3_205

M3 - Article

C2 - 9331789

AN - SCOPUS:0030771818

SN - 0065-2598

VL - 418

SP - 863

EP - 868

JO - Advances in experimental medicine and biology

JF - Advances in experimental medicine and biology

ER -

Group A and group B streptococcal vaccine development - A round table presentation

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this